Alimentary Pharmacology and Therapeutics
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission
2020
-
Systematic review with meta‐analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease
2017
-
Airway inflammation and asthma.
1996
-
The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD-An Umbrella Review..
61:1854-1871.
2025
-
Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study.
2025
-
Clinical Trial: Dose-Finding Study of Linaprazan Glurate, A Novel Potassium-Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis..
61:1590-1602.
2025
-
Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements..
61:636-650.
2025
-
Meta-Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials..
61:32-43.
2025
-
Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium..
60:1512-1524.
2024
-
Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low-Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply..
60:1652-1653.
2024
-
Corrigendum to "The aging gastrointestinal tract: Epidemiology and clinical significance of disorders of gut-brain interaction in the older general population"..
60:1507.
2024
-
Letter: Social work and clinical synergy-Optimizing health interventions for elderly DGBI populations: Authors' reply..
60:1145-1146.
2024
-
Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trial.
60:737-748.
2024
-
The aging gastrointestinal tract: Epidemiology and clinical significance of disorders of gut‐brain interaction in the older general population.
60:446-456.
2024
-
Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms.
59:852-864.
2024
-
Editorial: Moving towards prognostic endoscopic scoring in IBD.
59:132-133.
2024
-
Editorial: On‐demand vonoprazan forNERD– when should it be ‘demanded’? Authors' reply.
58:1231-1231.
2023
-
Randomised clinical trial: Efficacy and safety of on‐demand vonoprazan versus placebo for non‐erosive reflux disease.
58:1016-1027.
2023
-
Systematic review with meta‐analysis: Medical therapies for treatment of ulcerative proctitis.
58:740-762.
2023
-
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.
58:16-25.
2023
-
Letter: Potassium‐competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication—a retrospective multicentre‐cohort analysis. Authors' reply.
57:1199-1200.
2023
-
Meta‐analysis: Use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression.
57:653-665.
2023
-
Letter: efficacy of peppermint oil in irritable bowel syndrome—authors' reply.
56:1217-1218.
2022
-
Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs.
56:1074-1075.
2022
-
Systematic review and meta‐analysis: efficacy of peppermint oil in irritable bowel syndrome.
56:932-941.
2022
-
Resolution of dominant patient‐reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease.
55:1151-1159.
2022
-
Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn’s disease? Authors’ reply.
55:1040-1041.
2022
-
Editorial: methotrexate in patients with Crohn's disease refractory to anti‐TNF therapy—moving backwards yet forward?.
53:950-951.
2021
-
Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms.
53:253-264.
2021
-
Editorial: acid suppression with potassium‐competitive acid blockers dismissing genotype concerns.
53:187-188.
2021
-
Systematic review and network meta‐analysis: efficacy of drugs for functional dyspepsia.
53:8-21.
2021
-
Letter: mesalazine—a safe drug with rare serious adverse events? Authors’ reply.
51:1212-1212.
2020
-
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply.
51:997-998.
2020
-
Prevalence of endoscopic improvement and remission according to patient‐reported outcomes in ulcerative colitis.
51:435-445.
2020
-
Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
51:271-280.
2020
-
Editorial: potassium‐competitive acid blockers for acid‐related diseases—tegoprazan, a new kid on the block.
50:960-962.
2019
-
Editorial: the overlap between dyspepsia and gastro‐oesophageal reflux—is duodenal eosinophilia the missing link?.
50:454-455.
2019
-
Systematic review with meta‐analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease.
50:121-131.
2019
-
Letter: meta‐analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors’ reply.
49:1254-1255.
2019
-
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission – confounded by the gut microbiome? Authors’ reply.
49:1088-1089.
2019
-
Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.
49:723-732.
2019
-
Editorial: ulcer‐related vs non‐ulcer‐nonvariceal upper gastrointestinal bleeding—which has worse outcomes?.
49:818-819.
2019
-
Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome.
48:1044-1060.
2018
-
Systematic review: safety of mesalazine in ulcerative colitis.
47:1597-1609.
2018
-
Editorial: the prevalence of Helicobacter pylori infection worldwide—knowns and unknowns.
47:1330-1331.
2018
-
The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy‐refractory bleeding, rebleeding or mortality in peptic ulcer bleeding.
46:355-363.
2017
-
Systematic review with meta‐analysis: proximal disease extension in limited ulcerative colitis.
45:1481-1492.
2017
-
Editorial: latent class analysis to improve confidence in the diagnosis of IBS – authors’ reply.
45:1268-1269.
2017
-
Letter: NICE referral criteria for lower gastrointestinal alarm features – not ideal but not poor either. Authors' reply.
45:1176-1176.
2017
-
Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis.
45:824-832.
2017
-
Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
45:617-630.
2017
-
Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care.
45:91-99.
2017
-
Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease – should one consider disease location? Authors’ reply.
44:772-773.
2016
-
An index with improved diagnostic accuracy for the diagnosis of Crohn's disease derived from the Lennard‐Jones criteria.
44:601-611.
2016
-
The efficacy and safety of either infliximab or adalimumab in 362 patients with anti‐TNF‐α naïve Crohn's disease.
44:170-180.
2016
-
Letter: mucosal healing is associated with improved long‐term outcomes in Crohn's disease – authors' reply.
43:1347-1348.
2016
-
Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease.
43:317-333.
2016
-
Editorial: towards extended acid suppression - the search continues.
42:1027-1029.
2015
-
Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating.
41:449-458.
2015
-
Editorial: healing of refractory reflux oesophagitis – an ongoing unmet clinical need.
40:987-989.
2014
-
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.
39:1126-1135.
2014
-
Commentary: independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer.
39:993-994.
2014
-
Characteristics of functional bowel disorder patients: a cross‐sectional survey using the Rome III criteria.
39:312-321.
2014
-
Meta-analysis: rectal indomethacin for the prevention of post-ERCP pancreatitis.
38:995-1001.
2013
-
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
38:447-459.
2013
-
Meta‐analysis: peri‐operative anti‐TNFα treatment and post‐operative complications in patients with inflammatory bowel disease.
37:1057-1064.
2013
-
Meta‐analysis: colonoscopic post‐polypectomy bleeding in patients on continued clopidogrel therapy.
37:947-952.
2013
-
The impact of intensifying acid suppression on sleep disturbance related to gastro‐oesophageal reflux disease in primary care.
37:730-737.
2013
-
The natural history of gastro‐oesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10‐year follow‐up study.
37:323-331.
2013
-
Review article: current treatment options and management of functional dyspepsia.
36:3-15.
2012
-
Commentary: what is the optimal PPI dosing following endoscopic haemostasis in acute ulcer bleeding?.
35:1351-1352.
2012
-
PPI co‐therapy did not adversely affect outcomes in clopidogrel users.
35:313-314.
2012
-
Sequential therapy – more studies are still required.
35:194-195.
2012
-
Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome.
34:374-383.
2011
-
Night-time intra-oesophageal bile and acid exposure in GERD patients failing PPI therapy.
33:1068-1069.
2011
-
Rabeprazole extended-release 50 mg compared with esomeprazole 40 mg and rabeprazole delayed release 20 mg.
33:1177-1179.
2011
-
Meta‐analysis: factors affecting placebo response rate in the irritable bowel syndrome.
32:144-158.
2010
-
Cost‐utility analysis of proton pump inhibitors and other gastro‐protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti‐inflammatory agents.
31:1354-1364.
2010
-
Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia.
31:1165-1177.
2010
-
The development and validation of a new coeliac disease quality of life survey (CD‐QOL).
31:666-675.
2010
-
The pharmacodynamics and pharmacokinetics of S‐tenatoprazole‐Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects.
31:648-657.
2010
-
Inaccurate endoscopy: a better explanation for placebo‐associated endoscopic ulcers: authors’ reply.
30:957-960.
2009
-
Meta‐analysis: incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo‐controlled NSAID trials.
30:197-209.
2009
-
10‐biomarker algorithm to identify irritable bowel syndrome.
30:95-96.
2009
-
Glucocorticoids can help in acute severe alcoholic hepatitis: authors’ reply.
30:93-95.
2009
-
Meta‐analysis: yield of diagnostic tests for coeliac disease in dyspepsia.
30:28-36.
2009
-
Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis ‐ results from the maintenance phase of the EXPO study.
29:1165-1171.
2009
-
Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis – results from the EXPO study.
29:959-966.
2009
-
Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
29:481-496.
2009
-
Fluctuation of gastrointestinal symptoms in the community: a 10‐year longitudinal follow‐up study.
28:1013-1020.
2008
-
Systematic review: persistence and severity in gastro‐oesophageal reflux disease.
28:841-853.
2008
-
Meta‐analysis: Helicobacter pylori‘test and treat’ compared with empirical acid suppression for managing dyspepsia.
28:534-544.
2008
-
Clinical trial design in adult reflux disease: a methodological workshop.
28:107-126.
2008
-
Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa‐2a plus ribavirin.
28:43-50.
2008
-
Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904‐Z.
28:187-199.
2008
-
Systematic review: glucocorticosteroids for alcoholic hepatitis – a Cochrane Hepato‐Biliary Group systematic review with meta‐analyses and trial sequential analyses of randomized clinical trials.
27:1167-1178.
2008
-
Mortality risks associated with Barrett’s oesophagus: authors' reply.
27:853-854.
2008
-
Mortality rates in patients with Barrett’s oesophagus.
27:316-320.
2008
-
New algorithm for the treatment of gastro‐oesophageal reflux disease.
27:249-256.
2008
-
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia‐related resource use.
26:1267-1275.
2007
-
Meta‐analysis: the use of non‐steroidal anti‐inflammatory drugs and pancreatic cancer risk for different exposure categories.
26:1089-1099.
2007
-
Overlap of gastro‐oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population.
26:453-461.
2007
-
Systematic review and meta‐analysis: the incidence and prognosis of post‐infectious irritable bowel syndrome.
26:535-544.
2007
-
Symptom overlap in patients with upper gastrointestinal complaints in the Canadian confirmatory acid suppression test (CAST) study: further psychometric validation of the reflux disease questionnaire.
25:1087-1097.
2007
-
GI Epidemiology: infection epidemiology and acute gastrointestinal infections.
25:669-674.
2007
-
The Short‐Form Leeds Dyspepsia Questionnaire validation study.
25:477-486.
2007
-
Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.
25:185-196.
2007
-
Injection of botulinum toxin before pneumatic dilatation in achalasia treatment: a randomized‐controlled trial.
24:983-989.
2006
-
Predictors of treatment response in patients with non‐erosive reflux disease.
24:371-376.
2006
-
Healing rates for moderate and severe oesophagitis: author's reply.
23:1374-1375.
2006
-
Levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure: how strong is the evidence?.
23:1283-1285.
2006
-
The prevalence of Barrett's oesophagus in a cohort of 1040 Canadian primary care patients with uninvestigated dyspepsia undergoing prompt endoscopy.
23:595-599.
2006
-
Errata.
23:449-449.
2006
-
Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.(vol 22, pg 803, 2005).
23:449-449.
2006
-
Validation of a 7‐point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials.
23:521-529.
2006
-
Validation of a symptom diary for patients with gastro‐oesophageal reflux disease.
23:531-541.
2006
-
Review article: the unmet needs in delayed‐release proton‐pump inhibitor therapy in 2005.
22:10-19.
2005
-
Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study1.
22:803-811.
2005
-
Proton‐pump inhibitor for peptic ulcer bleeding: Authors’ reply.
22:892-892.
2005
-
Lower oesophageal sphincter pressure and timed barium oesophagogram: two objective parameters in the non-invasive assessment of primary achalasia.
22:261-265.
2005
-
Review article: gastro‐oesophageal reflux disease – the extent of the problem.
22:11-19.
2005
-
Systematic review and meta‐analysis: proton‐pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay – results from the Cochrane Collaboration.
22:169-174.
2005
-
Gastro‐oesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South‐East Asian patients with dyspepsia.
21:1483-1490.
2005
-
Heartburn‐dominant, uninvestigated dyspepsia: a comparison of ‘PPI‐start’ and ‘H2‐RA‐start’ management strategies in primary care – the CADET‐HR Study.
21:1189-1202.
2005
-
Managing dyspepsia without alarm signs in primary care: new national guidance for England and Wales.
21:1135-1143.
2005
-
Systematic review and meta‐analysis: enhanced efficacy of proton‐pump inhibitor therapy for peptic ulcer bleeding in Asia – a post hoc analysis from the Cochrane Collaboration.
21:1055-1061.
2005
-
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
21:739-746.
2005
-
Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario.
20:1317-1322.
2004
-
Do physicians correctly assess patient symptom severity in gastro‐oesophageal reflux disease?.
20:1161-1169.
2004
-
International validation of ReQuest in patients with endoscopy‐negative gastro‐oesophageal reflux disease.
20:891-898.
2004
-
Review article: gastric pH — the most relevant predictor of benefit in reflux disease?.
20:19-26.
2004
-
Review article: towards consistency in the endoscopic diagnosis of Barrett's oesophagus and columnar metaplasia.
20:40-47.
2004
-
The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study. (vol 17, pg 1481, 2003).
20:702-702.
2004
-
Corrigenda.
20:702-702.
2004
-
Pneumatic balloon dilatation in achalasia: a prospective comparison of safety and efficacy with different balloon diameters.
20:431-436.
2004
-
Do we need a new gastro‐oesophageal reflux disease questionnaire?.
19:463-479.
2004
-
The methodological quality of trials affects estimates of treatment efficacy in functional (non‐ulcer) dyspepsia.
19:631-641.
2004
-
Economic evaluation of Helicobacter pylori eradication in the CADET‐Hp randomized controlled trial of H. pylori‐positive primary care patients with uninvestigated dyspepsia.
19:349-358.
2004
-
Should NSAID/low‐dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing.
19:9-16.
2004
-
Uninvestigated dyspepsia and non‐ulcer dyspepsia—the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy.
19:1-8.
2004
-
Impact of functional gastrointestinal disorders on health‐related quality of life: a population‐based case–control study.
19:233-242.
2004
-
Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.
18:705-711.
2003
-
Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.
18:705-711.
2003
-
The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study.
17:1481-1491.
2003
-
Mycophenolate mofetil in refractory inflammatory bowel disease.
17:1365-1369.
2003
-
The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET–PE) study.
17:1481-1491.
2003
-
Systematic review: antacids, H2‐receptor antagonists, prokinetics, bismuth and sucralfate therapy for non‐ulcer dyspepsia.
17:1215-1227.
2003
-
Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
17:201-210.
2003
-
Complementary studies of the gastrointestinal safety of the cyclo‐oxygenase‐2‐selective inhibitor etoricoxib.
17:201-210.
2003
-
Acid suppression in healthy subjects following lansoprazole or pantoprazole.
16:425-433.
2002
-
The cost‐effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
16:559-568.
2002
-
Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report.
16:167-180.
2002
-
Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia.
15:1389-1396.
2001
-
Review article: should we kill or should we save Helicobacter pylori?.
15:51-59.
2001
-
Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers.
15:105-113.
2001
-
A randomized controlled trial to assess alendronate‐associated injury of the upper gastrointestinal tract.
14:1451-1457.
2000
-
Helicobacter pylori and gastric cancer − the clinicians' point of view.
14:48-54.
2000
-
Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
14:775-782.
2000
-
The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme.
14:719-728.
2000
-
The effects of omeprazole on healing and appearance of small gastric and duodenal lesions during dosing with diclofenac in healthy subjects.
14:535-541.
2000
-
Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
14:345-352.
2000
-
The importance of clarithromycin dose in the management of H. pylori infection: a meta‐analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.
13:1693-1693.
1999
-
5‐Day H. pylori eradication.
13:1252-1252.
1999
-
Reply — 5‐Day H. pylori eradication.
13:1253-1253.
1999
-
Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan.
13:927-936.
1999
-
The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta‐analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.
13:719-729.
1999
-
Anti‐ulcerogenic properties of endothelin receptor antagonists in the rat.
13:537-544.
1999
-
The optimal antibiotic combination in a 5‐day Helicobacter pylori eradication regimen.
13:497-501.
1999
-
Clarithromycin‐based triple therapies.
13:437-438.
1999
-
Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection.
13:27-34.
1999
-
Olestra and its gastrointestinal safety.
12:1185-1200.
1998
-
Review article: olestra and its gastrointestinal safety.
12:1185-1200.
1998
-
The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia.
12:1257-1262.
1998
-
Dose–response relationship of lansoprazole to gastric acid antisecretory effects.
12:321-327.
1998
-
Letters to the Editors.
12:395-396.
1998
-
Clinical economics review: cost‐effectiveness of treatment alternatives for gastro‐oesophageal reflux disease.
10:865-873.
1996
-
Time to maximum effect of lansoprazole on gastric pH in normal male volunteers.
10:897-904.
1996
-
Effects of misoprostol on healing and prevention of biopsy‐induced gastroduodenal lesions occurring during the administration of diclofenac to volunteers.
10:563-569.
1996
-
Airway inflammation and asthma - Similarities and dissimilarities between asthma and inflammatory bowel diseases - Discussion.
10:32-35.
1996
-
Erratum: Effects of misoprostol on healing and prevention of biopsy-induced gastroduodenal lesions occurring during the administration of diclofenac to volunteers.
10:833.
1996
-
The efect of indornethacin‐induced gastric rnucosal injury on 24‐h intragastric acidity and plasma gastrin concentration in healthy volunteers.
9:625-631.
1995
-
Rectal aminosalicylate therapy for distal ulcerative colitis: a meta‐analysis.
9:293-300.
1995
-
The relationship between the control of pH and healing and symptom relief in gastro‐oesophageal reflux disease.
9:3-7.
1995
-
The rationale of acid suppression in the treatment of acid‐related disease..
8:3-10.
1994
-
Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration.
6:103-111.
1992
-
Twenty‐four‐hour intragastric acidity and nocturnal gastric secretion in gastric ulcer patients—the effects of cimetidine.
4:275-281.
1990
-
The relationship between suppression of acidity and gastric ulcer healing rates.
4:25-33.
1990
-
Does misoprostol given as a single large dose improve its antisecretory effect?.
3:403-407.
1989
-
The effect of tripotassium dicitrato bismuthate on pepsin activity.
3:381-385.
1989
-
THE ANTI-SECRETORY EFFECT AND PHARMACOKINETICS OF OMEPRAZOLE IN CHRONIC LIVER-DISEASE.
2:429-437.
1988
-
Twenty‐four‐hour intragastric measurements in twenty healthy subjects: effect of enisoprost, a novel and potent antisecretory and antipeptic synthetic E1 prostaglandin.
2:325-336.
1988
-
Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE1 analogue.
1:305-313.
1987
-
The effects of intravenous famotidine on pentagastrin‐stimulated gastric secretion in man.
1:125-132.
1987
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)